SUSTANON 350

PRODUCT OVERVIEW

Specification	Details
Generic Name	Sustanon 350
Drug Class	Androgen and Anabolic Steroid
Active Ingredient	Testosterone Propionate, Testosterone Phenylpropionate, Testosterone Isocaproate, Testosterone Decanoate
Total Testosterone Content	350 mg/mL
Administration Route	Intramuscular Injection
Formulation Type	Multi-Ester Testosterone Blend
Approximate Half-Life	Approximately 15-21 Days (Overall Blend)
Release Profile	Immediate, Intermediate, and Long-Acting Release
Bioavailability	High After Intramuscular Administration
Primary Medical Use	Testosterone Replacement Therapy in Men With Confirmed Testosterone Deficiency

INTRODUCTION

Sustanon 350 is a high-concentration multi-ester testosterone formulation designed to provide rapid onset together with sustained blood hormone levels through a single injection. Each milliliter contains 350 mg of testosterone esters. Sustanon 350 combines four different testosterone esters with different physicochemical properties, allowing immediate testosterone release from the shorter esters while maintaining sustained hormone concentrations through intermediate and long-acting esters. This multi-ester approach differs from single-ester testosterone products, which release testosterone more uniformly but with a slower initial rise and a longer overall duration of action.

Four decades of scientific investigation, multi-ester testosterone preparations have contributed significantly to advances in:

- Testosterone physiology
- Androgen receptor biology
- Hormone replacement therapy
- Testosterone pharmacokinetics

HISTORY

The discovery of testosterone represented one of the most significant milestones in endocrinology and hormone science.

Following the successful synthesis of testosterone, researchers developed multiple esterified derivatives to improve hormone stability, modify absorption characteristics, and extend biological activity.

Multi-ester testosterone formulations were later introduced to combine rapid hormone availability with prolonged release following a single intramuscular injection.

Sustanon 350 combines four pharmaceutical concept by combining four testosterone esters with complementary pharmacokinetic properties while providing a higher total testosterone concentration than traditional Sustanon formulations.

CHEMICAL STRUCTURE

Sustanon 350 is a pharmaceutical combination composed of four esterified testosterone molecules.

Each ester contains the same active molecular structure, resulting in different absorption rates and durations of activity following intramuscular administration.

The four testosterone esters included in Sustanon 350 are:

- Testosterone Propionate — 50 mg
- Testosterone Phenylpropionate — 75 mg
- Testosterone Isocaproate — 100 mg
- Testosterone Decanoate — 125 mg

Following enzymatic cleavage of each ester bond, biologically active testosterone is released and interacts with androgen receptors throughout the body.

CHEMICAL PROFILE

Parameter	Information
Formulation Type	Multi-Ester Testosterone Blend
Active Hormone	Testosterone
Number of Esters	Four
Ester Components	Propionate, Phenylpropionate, Isocaproate, Decanoate
Hormone Classification	Androgen
Administration Route	Intramuscular Injection
Total Strength	350 mg/mL

PHARMACOLOGY

Following intramuscular administration, each testosterone ester is absorbed according to its individual pharmacokinetic characteristics.

The shorter esters contribute rapid hormone availability, while the intermediate esters maintain hormone concentrations during the intermediate phase, and the long-chain decanoate ester provides prolonged testosterone release over an extended period.

Once released, testosterone interacts with androgen receptors located throughout multiple tissues, including:

- Skeletal muscle
- Bone
- Brain
- Liver
- Skin
- Reproductive tissues
- Central nervous system tissues

Testosterone also undergoes enzymatic conversion into biologically active metabolites.

Conversion Pathway	Enzyme	Product
Testosterone → DHT	5-alpha reductase	Dihydrotestosterone
Testosterone → Estradiol	Aromatase	Estradiol (E2)

MECHANISM OF ACTION

Testosterone produces its biological effects primarily through activation of intracellular androgen receptors.

The mechanism involves several biological stages:

- Testosterone enters target cells.
- Testosterone binds to androgen receptors.
- The androgen–receptor complex becomes activated.
- The complex moves into the nucleus.
- Interaction with androgen response elements occurs on DNA.
- Gene transcription is modified.
- Cellular protein production is stimulated.

Androgen receptor activation contributes to:

- Protein metabolism
- Muscle tissue maintenance
- Red blood cell production
- Neuromuscular function
- Bone density support
- Hormonal signaling regulation

PHARMACODYNAMICS

Sustanon 350 affects multiple physiological systems through androgen receptor signaling.

SKELETAL MUSCLE SYSTEM

Testosterone contributes to normal muscle physiology through:

- Stimulation of protein metabolism
- Support of muscle tissue maintenance
- Enhancement of muscle protein synthesis
- Regulation of muscle strength

Androgen signaling plays an important role in maintaining normal muscle structure and function.

SKELETAL SYSTEM

Testosterone contributes to skeletal health by influencing:

- Bone mineral density
- Osteoblast activity
- Bone remodeling processes
- Skeletal maintenance

Testosterone also contributes indirectly through conversion to estradiol, which has an important role in bone metabolism.

HEMATOLOGICAL SYSTEM

Testosterone influences erythropoiesis, the biological process responsible for red blood cell production.

Physiological effects include:

- Regulation of erythropoietin activity
- Red blood cell production support
- Influence on oxygen transport capacity

NERVOUS SYSTEM

Androgen receptors are distributed throughout the nervous system.

Testosterone contributes to:

- Neural regulation
- Cognitive function
- Peripheral nerve coordination
- Central nervous system signaling

REPRODUCTIVE SYSTEM

Testosterone is essential for normal reproductive physiology.

Functions include:

- Development of male characteristics
- Support of libido
- Maintenance of androgen-dependent tissues
- Hormonal balance

PHARMACOKINETICS

Following intramuscular administration, the four testosterone esters are released sequentially according to their individual pharmacokinetic characteristics.

The shorter esters contribute rapid hormone availability, Testosterone Phenylpropionate and Testosterone Isocaproate provide intermediate release, while Testosterone Decanoate maintains prolonged testosterone concentrations over time.

This sequential release profile produces immediate onset together with sustained testosterone exposure while maintaining relatively stable circulating testosterone concentrations.

PHARMACOKINETIC PROFILE

Parameter	Description
Formulation Type	Multi-Ester Testosterone Blend
Absorption	Sequential release from intramuscular depot
Release Pattern	Immediate, Intermediate and Long-Acting
Half-Life	Approximately 15-21 Days (Overall Blend)
Duration of Activity	Extended
Plasma Stability	Sustained testosterone availability
Protein Binding	High
Metabolism	Primarily hepatic
Active Hormone	Testosterone
Elimination	Urinary excretion of metabolites

PHYSIOLOGICAL EFFECTS

Potential testosterone activity contributes to:

Muscle Function
- Maintenance of lean body tissue
- Regulation of protein metabolism
- Support of normal muscle physiology

Bone Health
- Bone remodeling
- Mineral density maintenance
- Skeletal integrity

Metabolic Function
- Protein metabolism
- Red blood cell production
- Energy balance

Reproductive Health
- Sexual development
- Libido regulation
- Androgen-dependent functions

General Physiology
- Neuromuscular function
- Hormonal balance
- Endocrine function

CLINICAL APPLICATIONS

Sustanon 350 may be used under medical supervision for individuals with confirmed testosterone deficiency.

Clinical evaluation may include:

- Medical history
- Physical examination
- Hormonal testing
- Assessment of underlying causes

Potential medical applications include:

- Testosterone deficiency conditions
- Hypogonadism management
- Long-term management of androgen deficiency states

SAFETY CONSIDERATIONS

Testosterone therapy requires individualized medical evaluation and regular monitoring.

Important considerations include:

Cardiovascular Health
- Blood parameters
- Lipid profiles
- Prostate health

- Liver and kidney function
- Individual response

POTENTIAL ADVERSE EFFECTS

Possible adverse effects may include:

Endocrine Effects
- Suppression of natural testosterone production
- Changes in estrogen balance
- Hormonal fluctuations

Dermatological Effects
- Acne
- Increased skin oil production
- Hair loss in genetically predisposed individuals

Cardiovascular Effects
- Changes in lipid profile
- Blood pressure changes
- Red blood cell changes

Reproductive Effects
- Changes in sperm production
- Effects on fertility
- Changes in reproductive hormone regulation

CONTRAINDICATIONS

Testosterone therapy may not be appropriate for individuals with:

Condition	Reason
Prostate Cancer	Potential androgen sensitivity
Male Breast Cancer	Hormone-sensitive condition
Elevated Hematocrit	Increased blood viscosity concerns
Severe Untreated Medical Conditions	Requires medical evaluation
Known Hypersensitivity	Risk of allergic reaction

DRUG INTERACTIONS

Potential interactions may occur with:

Anticoagulants
Testosterone may influence anticoagulant effects and require monitoring.

Diabetes Medications
Hormonal changes may influence glucose metabolism.

Corticosteroids
Combined use may affect balance and metabolic parameters.

Other Hormonal Therapies
Requires professional medical evaluation.

LABORATORY MONITORING

Laboratory Test	Purpose
Total Testosterone	Evaluate hormone status
Free Testosterone	Assess biologically available hormone
SHBG	Evaluate hormone transport
Estradiol (E2)	Monitor estrogen balance
CBC	Assess blood parameters
Hematocrit	Monitor red blood cell concentration
Lipid Profile	Evaluate cardiovascular markers
Liver Function Tests	Assess metabolic health
Kidney Function Tests	Evaluate renal status
PSA (When Appropriate)	Monitor prostate health

STORAGE & STABILITY

- Store according to official product labeling.
- Protect from excessive heat and direct sunlight.
- Do not freeze.
- Maintain original packaging integrity.
- Keep away from children.
- Inspect packaging before use.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

- Batch number tracking
- Manufacturing date verification
- Expiration date verification
- QR authentication system
- Authorized distribution verification

NEXON emphasizes transparency, traceability, and product quality control.

FREQUENTLY ASKED QUESTIONS

What is Sustanon 350?
Sustanon 350 is a high-concentration multi-ester testosterone formulation containing four testosterone esters designed to provide rapid and sustained testosterone release following intramuscular administration.

How many testosterone esters are included in Sustanon 350?
Sustanon 350 contains Testosterone Propionate (50 mg), Testosterone Phenylpropionate (75 mg), Testosterone Isocaproate (75 mg), and Testosterone Decanoate (150 mg) per milliliter.

How is Sustanon 350 different from Testosterone Cypionate?
Sustanon 350 combines four testosterone esters with different release characteristics, providing immediate, intermediate, and prolonged testosterone availability, whereas Testosterone Cypionate contains a single long-acting ester.

Why does Sustanon 350 contain multiple testosterone esters?
Multiple esters are used to combine immediate, intermediate, and long-acting release profiles to provide rapid initial testosterone availability while maintaining sustained hormone release over an extended period.

Is the testosterone in Sustanon 350 identical to natural testosterone?
After ester enzymatic cleavage and ester bond, the released active hormone is chemically identical to endogenous testosterone produced by the human body.

NEXON QUALITY COMMITMENT

NEXON maintains strict manufacturing standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

1. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.

2. Handelsman DJ. Pharmacology of testosterone preparations.

3. Swerdloff RS, Testosterone therapy in men with androgen deficiency.

4. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens.

5. Snyder PJ, et al. Effects of Testosterone Treatment in Older Men.

6. Shrestha S, et al. Testosterone Dose-Response Relationships in Healthy Young Men.

7. Travis AM. Testosterone and metabolic health.

8. Matsumoto AM. Androgen replacement therapy and male hypogonadism.